
    
      This study was a double-blind, randomized, parallel group, proof of concept study patients
      with post-traumatic osteoarthritis (PTOA) of the knee. Approximately 124 eligible patients
      were intended to be randomized to one of the two treatment groups (1:1) and treated with a
      single intra-articular (IA) injection of:

        -  32 mg of FX006

        -  40 mg of KenalogÂ®-40 (triamcinolone acetonide injectable suspension, USP)

      Each prospective patient underwent a screening evaluation to confirm a diagnosis of PTOA of
      the knee and concurrence with all other eligibility criteria. Patients were be treated on Day
      1 (Baseline) and returned to the clinic at Weeks 4, 8 and 12 for evaluation of safety and
      efficacy.
    
  